493 related articles for article (PubMed ID: 21834960)
41. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
[TBL] [Abstract][Full Text] [Related]
42. Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).
Ray-Coquard I; Italiano A; Bompas E; Le Cesne A; Robin YM; Chevreau C; Bay JO; Bousquet G; Piperno-Neumann S; Isambert N; Lemaitre L; Fournier C; Gauthier E; Collard O; Cupissol D; Clisant S; Blay JY; Penel N;
Oncologist; 2012; 17(2):260-6. PubMed ID: 22285963
[TBL] [Abstract][Full Text] [Related]
43. Experience of sorafenib treatment in differentiated thyroid cancer from Taiwan.
Lin CY; Chang JS; Huang SM; Hung CJ; Hung CL; Chang CT; Yang HR; Hsieh TC; Huang YH; Tsai HJ
J Formos Med Assoc; 2021 Jan; 120(1 Pt 1):189-195. PubMed ID: 32402521
[TBL] [Abstract][Full Text] [Related]
44. Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study.
Zhao JD; Liu J; Ren ZG; Gu K; Zhou ZH; Li WT; Chen Z; Xu ZY; Liu LM; Jiang GL
Radiat Oncol; 2010 Feb; 5():12. PubMed ID: 20149262
[TBL] [Abstract][Full Text] [Related]
45. The successful use of sorafenib to treat pediatric papillary thyroid carcinoma.
Waguespack SG; Sherman SI; Williams MD; Clayman GL; Herzog CE
Thyroid; 2009 Apr; 19(4):407-12. PubMed ID: 19355831
[TBL] [Abstract][Full Text] [Related]
46. RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.
Baselga J; Zamagni C; Gómez P; Bermejo B; Nagai SE; Melichar B; Chan A; Mángel L; Bergh J; Costa F; Gómez HL; Gradishar WJ; Hudis CA; Rapoport BL; Roché H; Maeda P; Huang L; Meinhardt G; Zhang J; Schwartzberg LS
Clin Breast Cancer; 2017 Dec; 17(8):585-594.e4. PubMed ID: 28830796
[TBL] [Abstract][Full Text] [Related]
47. Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer.
Lin Y; Qin S; Yang H; Shi F; Yang A; Han X; Liu B; Li Z; Ji Q; Tang L; Deng Z; Ding Y; Fu W; Xie X; Li L; He X; Lv Z; Ma Q; Shen Z; Guo Z; Chen Z; Cui Y; Tan J; Gao Z; Jing S; Lu K; Luo X; Zhang Y; Fang Y; Li Z; Cheng Y; Lei S; Luan S; Chen G; Wang G; Wu L; Liu L
Clin Cancer Res; 2023 Aug; 29(15):2791-2799. PubMed ID: 37184934
[TBL] [Abstract][Full Text] [Related]
48. FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.
Nair A; Lemery SJ; Yang J; Marathe A; Zhao L; Zhao H; Jiang X; He K; Ladouceur G; Mitra AK; Zhou L; Fox E; Aungst S; Helms W; Keegan P; Pazdur R
Clin Cancer Res; 2015 Dec; 21(23):5205-8. PubMed ID: 26324740
[TBL] [Abstract][Full Text] [Related]
49. Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.
Brose MS; Worden FP; Newbold KL; Guo M; Hurria A
J Clin Oncol; 2017 Aug; 35(23):2692-2699. PubMed ID: 28613956
[TBL] [Abstract][Full Text] [Related]
50. Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
Goto H; Kiyota N; Otsuki N; Imamura Y; Chayahara N; Suto H; Nagatani Y; Toyoda M; Mukohara T; Nibu KI; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
Auris Nasus Larynx; 2018 Dec; 45(6):1249-1252. PubMed ID: 29779695
[TBL] [Abstract][Full Text] [Related]
51. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
[TBL] [Abstract][Full Text] [Related]
52. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy.
Locati LD; Piovesan A; Durante C; Bregni M; Castagna MG; Zovato S; Giusti M; Ibrahim T; Puxeddu E; Fedele G; Pellegriti G; Rinaldi G; Giuffrida D; Verderame F; Bertolini F; Bergamini C; Nervo A; Grani G; Rizzati S; Morelli S; Puliafito I; Elisei R
Eur J Cancer; 2019 Sep; 118():35-40. PubMed ID: 31299580
[TBL] [Abstract][Full Text] [Related]
53. Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma.
Chen L; Shen Y; Luo Q; Yu Y; Lu H; Zhu R
Thyroid; 2011 Feb; 21(2):119-24. PubMed ID: 21186953
[TBL] [Abstract][Full Text] [Related]
54. The urokinase plasminogen activator system in metastatic papillary thyroid carcinoma: a potential therapeutic target.
Nowicki TS; Moscatello AL; Shin E; Schantz S; Tiwari RK; Geliebter J
J Clin Endocrinol Metab; 2011 Oct; 96(10):3062-4. PubMed ID: 21832115
[No Abstract] [Full Text] [Related]
55. Sorafenib in metastatic thyroid cancer.
Capdevila J; Iglesias L; Halperin I; Segura A; Martínez-Trufero J; Vaz MÁ; Corral J; Obiols G; Grande E; Grau JJ; Tabernero J
Endocr Relat Cancer; 2012 Apr; 19(2):209-16. PubMed ID: 22285864
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
Hong DS; Cabanillas ME; Wheler J; Naing A; Tsimberidou AM; Ye L; Busaidy NL; Waguespack SG; Hernandez M; El Naggar AK; Bidyasar S; Wright J; Sherman SI; Kurzrock R
J Clin Endocrinol Metab; 2011 Apr; 96(4):997-1005. PubMed ID: 21289252
[TBL] [Abstract][Full Text] [Related]
57. Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA).
Ho AL; Dedecjus M; Wirth LJ; Tuttle RM; Inabnet WB; Tennvall J; Vaisman F; Bastholt L; Gianoukakis AG; Rodien P; Paschke R; Elisei R; Viola D; So K; Carroll D; Hovey T; Thakre B; Fagin JA;
J Clin Oncol; 2022 Jun; 40(17):1870-1878. PubMed ID: 35192411
[TBL] [Abstract][Full Text] [Related]
58. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib.
Dadu R; Devine C; Hernandez M; Waguespack SG; Busaidy NL; Hu MI; Jimenez C; Habra MA; Sellin RV; Ying AK; Cote GJ; Sherman SI; Cabanillas ME
J Clin Endocrinol Metab; 2014 Jun; 99(6):2086-94. PubMed ID: 24628550
[TBL] [Abstract][Full Text] [Related]
59. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.
Rini B; Szczylik C; Tannir NM; Koralewski P; Tomczak P; Deptala A; Dirix LY; Fishman M; Ramlau R; Ravaud A; Rogowski W; Kracht K; Sun YN; Bass MB; Puhlmann M; Escudier B
Cancer; 2012 Dec; 118(24):6152-61. PubMed ID: 22692704
[TBL] [Abstract][Full Text] [Related]
60. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
Lam ET; Ringel MD; Kloos RT; Prior TW; Knopp MV; Liang J; Sammet S; Hall NC; Wakely PE; Vasko VV; Saji M; Snyder PJ; Wei L; Arbogast D; Collamore M; Wright JJ; Moley JF; Villalona-Calero MA; Shah MH
J Clin Oncol; 2010 May; 28(14):2323-30. PubMed ID: 20368568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
